TrialCurveTALAPRO-2 (HRR-deficient cohort): reconstructed Kaplan–Meier curves
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Med. 2023 Dec 4;30(1):257–64. doi: 10.1038/s41591-023-02704-x |
|---|---|
| DOI | 10.1038/s41591-023-02704-x |
| Registry | NCT03395197 |
| Phase | Phase 3 |
| Conditions | mCRPC |
| Interventions | Talazoparib with enzalutamide, Placebo with enzalutamide |
| Sponsor | Pfizer |
| Enrolment | 1054 |
| Source licence | Figure published under CC BY 4.0 |
Radiographic progression-free survival (BICR) — Patients with any HRR gene alteration (HRR-deficient intention-to-treat population)
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Talazoparib + enzalutamide not reached; Placebo + enzalutamide 12.4 months. Survival at 12 months: Talazoparib + enzalutamide 76%; Placebo + enzalutamide 51%. Hazard ratio Talazoparib + enzalutamide vs Placebo + enzalutamide 0.45 (95% CI 0.33–0.62).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Talazoparib + enzalutamide | 200 | 67 | not reached |
| Placebo + enzalutamide | 199 | 104 | 12.4 |
- Talazoparib + enzalutamide vs Placebo + enzalutamide: reconstructed HR 0.45 (95% CI 0.33–0.62)
Landmark survival (reconstructed)
| Time | Talazoparib + enzalutamide | Placebo + enzalutamide |
|---|---|---|
| 6 mo | 91.1% | 77.0% |
| 12 mo | 76.3% | 50.6% |
| 18 mo | 61.5% | 39.0% |
| 24 mo | 55.4% | 33.8% |
| 36 mo | 50.4% | — |
Checks against the published figure
- Placebo + enzalutamide median: printed 13.8, reconstructed 12.4 pass
- Talazoparib + enzalutamide events: printed 66, reconstructed 67 pass
- Talazoparib + enzalutamide n: printed 200, reconstructed 200 pass
- Placebo + enzalutamide events: printed 104, reconstructed 104 pass
- Placebo + enzalutamide n: printed 199, reconstructed 199 pass
- hazard ratio (direction inferred): printed 0.45, reconstructed 0.454 pass
Overall survival (interim analysis) — HRR-deficient intention-to-treat population
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Talazoparib + enzalutamide not reached; Placebo + enzalutamide 31.4 months. Survival at 12 months: Talazoparib + enzalutamide 91%; Placebo + enzalutamide 88%. Hazard ratio Talazoparib + enzalutamide vs Placebo + enzalutamide 0.69 (95% CI 0.46–1.02).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Talazoparib + enzalutamide | 200 | 44 | not reached |
| Placebo + enzalutamide | 199 | 55 | 31.4 |
- Talazoparib + enzalutamide vs Placebo + enzalutamide: reconstructed HR 0.69 (95% CI 0.46–1.02)
Landmark survival (reconstructed)
| Time | Talazoparib + enzalutamide | Placebo + enzalutamide |
|---|---|---|
| 6 mo | 100.0% | 95.4% |
| 12 mo | 91.3% | 88.0% |
| 18 mo | 82.3% | 76.3% |
| 24 mo | 75.9% | 67.4% |
| 36 mo | 64.3% | 41.4% |
Checks against the published figure
- Placebo + enzalutamide median: printed 33.7, reconstructed 31.4 pass
- Talazoparib + enzalutamide events: printed 43, reconstructed 44 pass
- Talazoparib + enzalutamide n: printed 200, reconstructed 200 pass
- Placebo + enzalutamide events: printed 53, reconstructed 55 pass
- Placebo + enzalutamide n: printed 199, reconstructed 199 pass
- hazard ratio (direction inferred): printed 0.69, reconstructed 0.688 pass
Time to PSA progression — HRR-deficient intention-to-treat population
From figure panel c · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Talazoparib + enzalutamide 28.6 months; Placebo + enzalutamide 11.3 months. Survival at 12 months: Talazoparib + enzalutamide 74%; Placebo + enzalutamide 46%. Hazard ratio Talazoparib + enzalutamide vs Placebo + enzalutamide 0.39 (95% CI 0.28–0.54).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Talazoparib + enzalutamide | 200 | 56 | 28.6 |
| Placebo + enzalutamide | 199 | 94 | 11.3 |
- Talazoparib + enzalutamide vs Placebo + enzalutamide: reconstructed HR 0.39 (95% CI 0.28–0.54)
Landmark survival (reconstructed)
| Time | Talazoparib + enzalutamide | Placebo + enzalutamide |
|---|---|---|
| 6 mo | 91.2% | 77.4% |
| 12 mo | 74.4% | 46.5% |
| 18 mo | 60.4% | 33.8% |
| 24 mo | 60.4% | 25.2% |
| 36 mo | 47.2% | — |
Checks against the published figure
- Talazoparib + enzalutamide median: printed 28.6, reconstructed 28.6 pass
- Placebo + enzalutamide median: printed 11.1, reconstructed 11.3 pass
- Talazoparib + enzalutamide events: printed 59, reconstructed 56 pass
- Talazoparib + enzalutamide n: printed 200, reconstructed 200 pass
- Placebo + enzalutamide events: printed 96, reconstructed 94 pass
- Placebo + enzalutamide n: printed 199, reconstructed 199 pass
- hazard ratio (direction inferred): printed 0.41, reconstructed 0.388 pass
Time to initiation of cytotoxic chemotherapy — HRR-deficient intention-to-treat population
From figure panel d · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Talazoparib + enzalutamide not reached; Placebo + enzalutamide not reached. Survival at 12 months: Talazoparib + enzalutamide 89%; Placebo + enzalutamide 75%. Hazard ratio Talazoparib + enzalutamide vs Placebo + enzalutamide 0.49 (95% CI 0.33–0.72).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Talazoparib + enzalutamide | 200 | 40 | not reached |
| Placebo + enzalutamide | 199 | 67 | not reached |
- Talazoparib + enzalutamide vs Placebo + enzalutamide: reconstructed HR 0.49 (95% CI 0.33–0.72)
Landmark survival (reconstructed)
| Time | Talazoparib + enzalutamide | Placebo + enzalutamide |
|---|---|---|
| 6 mo | 96.4% | 87.6% |
| 12 mo | 89.2% | 74.7% |
| 18 mo | 78.3% | 62.8% |
| 24 mo | 72.4% | 57.2% |
| 36 mo | 70.7% | 54.2% |
Checks against the published figure
- Talazoparib + enzalutamide events: printed 38, reconstructed 40 pass
- Talazoparib + enzalutamide n: printed 200, reconstructed 200 pass
- Placebo + enzalutamide events: printed 65, reconstructed 67 pass
- Placebo + enzalutamide n: printed 199, reconstructed 199 pass
- hazard ratio (direction inferred): printed 0.46, reconstructed 0.486 pass
PFS2 (investigator-assessed) — HRR-deficient intention-to-treat population
From figure panel e · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Talazoparib + enzalutamide 36.3 months; Placebo + enzalutamide 28.0 months. Survival at 12 months: Talazoparib + enzalutamide 90%; Placebo + enzalutamide 84%. Hazard ratio Talazoparib + enzalutamide vs Placebo + enzalutamide 0.58 (95% CI 0.40–0.85).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Talazoparib + enzalutamide | 200 | 46 | 36.3 |
| Placebo + enzalutamide | 199 | 64 | 28.0 |
- Talazoparib + enzalutamide vs Placebo + enzalutamide: reconstructed HR 0.58 (95% CI 0.40–0.85)
Landmark survival (reconstructed)
| Time | Talazoparib + enzalutamide | Placebo + enzalutamide |
|---|---|---|
| 6 mo | 98.5% | 95.3% |
| 12 mo | 90.4% | 83.9% |
| 18 mo | 80.6% | 69.1% |
| 24 mo | 72.2% | 60.4% |
| 36 mo | 61.3% | 33.7% |
Checks against the published figure
- Talazoparib + enzalutamide median: printed 36.4, reconstructed 36.3 pass
- Placebo + enzalutamide median: printed 28.1, reconstructed 28 pass
- Talazoparib + enzalutamide events: printed 44, reconstructed 46 pass
- Talazoparib + enzalutamide n: printed 200, reconstructed 200 pass
- Placebo + enzalutamide events: printed 61, reconstructed 64 pass
- Placebo + enzalutamide n: printed 199, reconstructed 199 pass
- hazard ratio (direction inferred): printed 0.57, reconstructed 0.583 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/talapro-2-hrr-deficient-cohort-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/talapro-2-hrr-deficient-cohort-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Nat Med. 2023 Dec 4;30(1):257–64. doi: 10.1038/s41591-023-02704-x doi:10.1038/s41591-023-02704-x. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/talapro-2-hrr-deficient-cohort
Report a problem with these data
Related trials
- AMPLITUDE: Investigator-assessed radiographic progression-free survival; Overall survival; Radiograph
- STAMPEDE (radiotherapy to the primary tumor): Failure-free survival; Overall survival
- Aglatimagene besadenovec + radiotherapy in prostate cancer: Disease-free survival; Prostate cancer-specific disease-free survival
- KEYNOTE-045 (Japanese subgroup): Duration of response; Overall survival; Progression-free survival
- ESCAPE (metastatic renal cell carcinoma): 1st-line (+ 2nd-line) progression-free survival; 2nd-line progression-free survival; Overa
- CLEAR (Japanese subgroup): Progression-free survival (independent imaging review per RECIST v1.1)
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials